tbuckley/cabot-search huggingface dataset:
Abstract 3474: GDF15 as a serum marker of cisplatin response in ovarian cancer cells.
Authors: Daisy I. Izaguirre, Suet Yan Kwan, Zhifei Zu, Yvonne T. Tsang-Lee, Kwong-Kwok Wong
Journal: Cancer Research (2013)

Abstract Ovarian cancer treatment consists of surgery followed by a chemotherapy combination entailing a platinum agent (cisplatin/carboplatin) and a taxane (paclitaxel). While 70-80% of patients initially respond to the standard treatment, the majority will relapse, and of these patients, 70-90% die because of drug resistance. Therefore, identifying markers that can predict therapeutic response and/or therapeutic targets is of great interest. To identify genes involved in chemoresistance, a microarray study of an ovarian cancer cell line (A2780) treated with varying doses of cisplatin and at varying time points was conducted. This study showed GDF15 had the highest fold-induction by cisplatin treatment. GDF15 induction by cisplatin was further validated by RT-PCR and Western blot analysis in the A2780 and 12 other cell lines with varying sensitivity/resistance to cisplatin. To further test whether GDF15 plays a role in cisplatin resistance, we knocked down its expression by esiRNA. GDF15 knockdown revealed an increase in the cisplatin IC50, suggesting that GDF15 sensitizes ovarian cancer cells to cisplatin. To determine whether GDF15 was also induced in vivo we injected mice intraperitoneally with either A2780 (cisplatin sensitive) or RMG1 (cisplatin resistant) cells. Once the tumors developed, the mice were treated with either 2.5 mg/kg or 5 mg/kg cisplatin and both the tumors and sera collected 24 and 48 hours after treatment. ELISA results on the serum showed an increase in GDF15 in mice after cisplatin treatment. Although there was no correlation between the two cisplatin doses used and GDF15 there was a correlation between GDF15 and tumor weight. Thus, our results suggest that GDF15 is induced by cisplatin both in vitro and in vivo and has a potential role as a serum biomarker to predict chemotherapeutic response. Citation Format: Daisy I. Izaguirre, Suet Yan Kwan, Zhifei Zu, Yvonne T. Tsang-Lee, Kwong-Kwok Wong. GDF15 as a serum marker of cisplatin response in ovarian cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2013-3474
Abstract 4309: Establishment of the chick chorioallantoic membrane (CAM) as an ex vivo model system to study mechanisms underlying epithelial ovarian tumour growth and metastasis
Authors: Jason Reed, Rohann Correa, Yudith Ramos-Valdes, Daniela M. Dinulescu, Barbara C. Vanderhyden, John D. Lewis, Gabriel E. DiMattia, Trevor G. Shepherd
Journal: Cancer Research (2011)

Abstract Epithelial ovarian cancer (EOC) accounts for approximately 90% of all human ovarian malignancies. Unfortunately, 75% of EOC cases are not diagnosed until advanced stages when the tumour has metastasized, after which standard therapy is less effective. Therefore, it remains vital to directly study the molecular and cellular mechanisms contributing to EOC metastasis in an experimentally-tractable system. The chick chorioallantoic membrane (CAM) is a highly-vascularized tissue responsible for gas and nutrient exchange in the avian embryo, and has been used extensively to study angiogenesis and tumour formation by highly-aggressive cancer cell lines. Herein, we report that ascites-derived primary human EOC cells and established EOC cell lines readily form well-vascularized tumours on the chick CAM. To investigate this property further, we have generated GFP-expressing clones from the mouse ovarian tumour cell lines MOSE-RM (oncogenic Ras &amp; Myc overexpression, SV40 TAg), MASC-2 (SV40 TAg), and 4306 (oncogenic Kras &amp; Pten-null) which will facilitate visualization of tumour growth on the CAM as well as complementary studies in syngeneic mouse models for future studies. Xenografts of MOSE-RM and 4306 cell lines onto the surface of the chick CAM establish tumours that are significantly larger in mass and size compared with MASC-2 cells. Importantly, EOC tumours grown on the chick CAM are histologically identical to those arising within the peritoneal cavity. MOSE-RM and 4306 cell lines promote angiogenesis using HUVEC cells and the chick CAM, whereas MASC-2 cells lack this ability. Overall, these results demonstrate that EOC tumour growth on the chick CAM can be exploited as a highly amenable model system for studying late-stage EOC metastasis. Our findings also indicate that neo-vascularization is an obligatory process for establishment of secondary tumours; thus, we are currently investigating signaling pathways that impact primary human EOC tumour growth and angiogenesis using the chick CAM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4309. doi:10.1158/1538-7445.AM2011-4309
FRI0452 Evaluation of the efficacy of education program for patients with rheumatoid arthritis
Authors: E.V. Orlova, L.N. Denisov, D.E. Karateev, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Education programs are an effective complement to traditional medical treatment, giving people with rheumatoid arthritis (RA) the strategies necessary to make daily decisions to cope with the disease [1,2]. <h3>Objectives</h3> To assess the effectiveness of therapeutic education for patients with RA. <h3>Methods</h3> 43 patients with RA were included. 23 RA patients participated in a education program, 20 received only drug therapy (control group). The education program consisted of 4 daily studies for 90 min. Effects of the program were evaluated after 6 months, comparatively to baseline, based on the following variables: Diseases Activity Score (DAS28), functional impairment (Health Assessment Questionnaire (HAQ)) and quality of life (Rheumatology Assessment Patient Index Data (RAPID3) by Multi-Dimensional HAQ (R798–NP2)). <h3>Results</h3> 6 months after therapeutic education DAS28 decreased by 1,33±0,26 (4,46±1,52 vs. 3,13±0,89, p&lt;0,05), HAQ – by 55,2% (1,65±0,83 vs. 0,74±0,45, ΔHAQ=0,91±0,54, p&lt;0,01), RAPID3 – by 49,9% (11,95±7,89 vs. 5,99±2,12, ΔRAPID3=5,96±0,92, p&lt;0,01). 6 months after participation in the educational program a good response to treatment by DAS28 criteria EULAR was observed more often (52,2% vs. 30,0% in the control group (p&lt;0,05)), and the number of patients, reported about improvement in their health, increased at 8,5 times (p&lt;0,01). After 6 months, there were statistically significant differences between groups for HAQ (p&lt;0,05) and RAPID3 (p&lt;0,05). <h3>Conclusions</h3> This study showed that the educational program tailored to patient needs helps to control the diseases activity, increases quality of life and improves functional ability of rheumatoid arthritis patients. <h3>References</h3> Riemsma R.P., Kirwan J.R., Taal E. et al. Patient education for adults with rheumatoid arthritis. Cochrane Database Sys Rev 2003;2:CD003688. Abourazzak F., El Mansouri L., Huchet D. et al. Long-term effects of therapeutic education for patients with rheumatoid arthritis. Joint, Bone, Spine: Revue du rhumatisme 2009;76(6):648–53. <h3>Disclosure of Interest</h3> None Declared
Hormonal Therapy of Cryptorchidism
Authors: Jacob Rajfer, David J. Handelsman, Ronald S. Swerdloff, Richard Hurwitz, Harold Kaplan, Thomas Vandergast, Richard M. Ehrlich
Journal: New England Journal of Medicine (1986)

We conducted a randomized, double-blind study comparing intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days) with parenteral human chorionic gonadotropin (3300 IU per week for four weeks) in the treatment of cryptorchidism in 33 boys one to five years old (29 with unilateral and 4 with bilateral cryptorchidism). Testicular descent into the scrotum occurred in 3 of the 16 patients (19 percent) treated with gonadotropin-releasing hormone and in 1 of the 17 (6 percent) treated with human chorionic gonadotropin (P = 0.23). The mean luteinizing hormone and testosterone levels were similar in both groups before treatment. During treatment, the testosterone levels were significantly increased in both groups, but higher levels occurred in the group treated with human chorionic gonadotropin (P<0.05). In a parallel (but uncontrolled) study of five boys with retractile testes (defined as a nonscrotal testis that could be manipulated into the bottom of the scrotum) who were originally excluded from the main protocol but were treated with the same regimen of human chorionic gonadotropin, descent into the scrotum occurred in all patients. We conclude that hormonal therapy with either gonadotropin-releasing hormone or human chorionic gonadotropin is, in most cases, ineffective in promoting testicular descent of true cryptorchid testes. However, short-term treatment with human chorionic gonadotropin is very effective in producing descent of retractile testes. These results suggest that the wide discrepancies in apparent efficacy in previous trials of hormonal therapy of cryptorchidism may have been due to inclusion in those studies of various proportions of patients with retractile testes. (N Engl J Med 1986; 314:466–70.)
Reserpine and Breast Cancer in a Retirement Community
Authors: Thomas M. Mack, Brian E. Henderson, Vibeke R. Gerkins, Mary Arthur, Joyce Baptista, Malcolm C. Pike
Journal: New England Journal of Medicine (1975)

In an attempt to confirm three reports suggesting a causal link between rauwolfia antihypertensive drugs and female breast carcinoma, all cases of such cancer appearing among the residents of an affluent retirement community were compared with controls chosen from a roster of all women in the same community. Most residents use a single care facility, and patterns of hypertension diagnosis, rauwolfia and other drug use, and medical-care-system patronage were abstracted from medical records. The prevalence of recorded rauwolfia use among the controls was 20 per cent, and that of other drug use was correspondingly high. The risk ratio for rauwolfia use was estimated to be 1.2 (95 per cent confidence interval, 0.7 to 2.2). Risk ratios between 1.0 and 2.0 were also found for other drug use and for measures of care-system patronage. These results do not support the hypothesis that reserpine causes breast cancer. (N Engl J Med 292:1366–1371, 1975)
The experience of West Nile virus integrated surveillance system in the Emilia-Romagna region: five years of implementation, Italy, 2009 to 2013
Authors: R Bellini, M Calzolari, A Mattivi, M Tamba, P Angelini, P Bonilauri, A Albieri, R Cagarelli, M Carrieri, M Dottori, A C Finarelli, P Gaibani, M P Landini, S Natalini, N Pascarelli, G Rossini, C Velati, C Vocale, E Bedeschi
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
ELEVATED RED BLOOD CELL DISTRIBUTION WIDTH WAS ASSOCIATED WITH ATTENUATED ENDOTHELIAL FUNCTION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Hiroyuki Suzuki, Yasushi Matsuzawa, Eiichi Akiyama, Masaaki Konishi, Naoki Nakayama, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Satoshi Umemura, Kazuo Kimura
Journal: Journal of the American College of Cardiology (2015)
Adult T-Cell Leukemia With Invasion by Malignant Cells of Both Parotid Glands Diagnosed by an Ga-67 Imaging:
Authors: JUN FUKUZAWA, TADAYUKI AKAISHI, HIDEICHI TANAKA, KYOKO NAKANISHI, MOTOI OKADA, TAKASHI HANEDA, KENJIRO KIKUCHI
Journal: Clinical Nuclear Medicine (1997)

Adult T-cell leukemia (ATL) shows several initial symptoms such as lymphadenopathy. Although oral cavity dryness is uncommon as an initial symptom of ATL, the authors encountered a case of a 74-year-old man patient who complained of this initial symptom. Routine examinations and clinical course indicated that he was suffering from ATL. Further examination such as Ga-67 citrate scintigraphy and a postmortem study showed that this symptom had been induced by the invasion by ATL cells of the bilateral parotid glands. Therefore, ATL should be considered in patients with an initial symptom of oral cavity dryness and enlargement of the bilateral parotid glands.
Abstract 4373: Color-coded real-time imaging of the interaction of mesenchymal stem cells and cancer cells
Authors: James Ke, Atsushi Suetsugu, Oscar K. Lee, Robert M. Hoffman
Journal: Cancer Research (2011)

Abstract Mesenchymal stem cells (MSC) have been reported to promote tumor growth and metastasis. Through paracrine effects, cytokines such as TGFβ or CCL5 produced by MSC play a role in modulating cancer cell behavior. However, the interaction between MSCs and cancer cells is not only via cytokines but involves physical contact as well. In this study, using GFP mesenchymal stem cells and RFP murine mammary cancer cells, the interaction between these cells types was imaged in vivo and vitro. Murine MSCs were isolated from GFP transgenic mice and 4T1 murine mammary cancer cells expressed RFP. Cells were co-cultured in vitro or co-implanted into the mouse mammary fat pad. Cell movement and distribution were recorded with fluorescence video microscopy. 4T1 cells had an epithelial shape and moved toward each other to form clusters when cultured alone. In contrast, 4T1 cells showed a stretched, spindle like morphology when interacting with MSCs. In vivo imaging with the Olympus OV-100 or IV-100, clearly visualized GFP-MSC and RFP-4T1 cells within tumors. When co-injected with MSCs, as few as 5 4T1-RFP cells could form a tumor but could not form tumors at the low cell number without MSCs. The results demonstrate that MSCs have a powerful effect on breast cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4373. doi:10.1158/1538-7445.AM2011-4373
AN APPROACH TO DECISION MAKING FOR LEFT VENTRICULAR THROMBUS AND INFECTION ASSOCIATED WITH TEMPORARY MECHANICAL CIRCULATORY SUPPORT: A MANAGEMENT CHALLENGE
Authors: Indrajeet Mahata, Zhaohui Li, Alaa Boulad, Sweta Singh, Abhishek Jaiswal, Thierry LeJemtel, Michael Weaver
Journal: Journal of the American College of Cardiology (2016)
Abstract 5394: Dual inhibition of the androgen receptor by ligand blockade and antisense-mediated downregulation is associated with synergistic antitumor activity model of prostate cancer
Authors: Yixian Zhang, Melissa Dumble, Stephen Castaneda, Mary Milesky, Steven Kim, Zhengxing Qu, Lee M. Greenberger, Ivan D. Horak
Journal: Cancer Research (2011)

Abstract Background: Although new agents to treat prostate cancer have recently been approved, and new investigational drugs (Abiraterone and MDV3100) that mediate hormone deprivation show promising data from late-stage clinical trials, these therapies typically extend overall survival up to 4 months in patients with advanced disease who have failed conventional androgen deprivation therapy. Hence, there continues to be great medical need. EZN-4176 is a novel LNA-based antisense oligonucleotide (EZN-4176) that down regulates androgen receptor (AR) expression. Previously, antitumor activity of EZN-4176 in multiple xenograft models including both androgen-sensitive and castrate-resistant tumors was shown. More importantly, a synergistic effect was also found when EZN-4176 was combined with MDV3100. Further exploration of the mechanistic underpinning of the effect was explored here. Methods: The mRNA, growth, luciferase activity, protein, and prostate specific antigen (PSA) were evaluated by qRT-PCR, MTT, SteadyGlo, western blot analysis, and ELISA assay, respectively. The effect of EZN-4176 on AR transcriptional activity was evaluated in cells stably express luciferase gene regulated by AR. In vivo, the effect of EZN-4176 on AR transcriptional activity was evaluated in a bone tumor model developed by intratibia injection of C4-2b-AR-luc cells. Results: Combination of EZN-4176 with MDV3100 resulted in a much improved inhibitory effect in colony formation assay in vitro. This effect was not associated with enhanced efficiency of AR mRNA down-modulation as treatment with EZN-4176 with or without MDV3100 showed similar effects on the level of AR mRNA. However, when AR transcriptional activity was examined, we found that the combined effect was greater than each agent alone. In C4-2b-AR-luc bone tumor model, EZN-4176 potently and specifically down-modulated AR-luciferase reporter activity. Further examinations of the anti-tumor effect in this model will help understand the potential of the combinatorial effect in a highly relevant disease model. Conclusions: Our preliminary data suggest that the synergistic anti-tumor effect of EZN-4176 in combination with MDV3100 is in part associated with much reduced transcriptional activity of AR. EZN-4176 alone or in combination with anti-androgens offers great potential in treating patients with advanced prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5394. doi:10.1158/1538-7445.AM2011-5394
AB0961 Differentiation of rabbit adipose tissue-derived stem cells into a chondrocyte-like phenotype “in vitro” facilitated by collagen type v
Authors: C. Goldenstein-Schainberg, I.B. Cruz, R. Fuller, A.P. Velosa, S. Carrasco, V. Capelozzi, N.H. Yoshinari, W.R. Teodoro
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoarthritis (OA) is a joint pain syndrome that leads to dysfunction consequent to joint degeneration. Current available therapiesforOAare mostly symptomatic with little influence onregenerativeaspects. Thoughanti-inflammatory drugshave aneffectonpain reductionandcontrol of inflammatory processes they may not be sufficientin more advanced stagesofcartilage degeneration. Among a variety of biological functions, including an anti-inflammatory effect, collagen V (COLV) regulates the diameter of collagen fibers with a relevant role in the development of functional tissues. <h3>Objectives</h3> To evaluate, in rabbits, the influence of COLV in the induction of differentiation of adipose tissue-derived stem cells to a chondrocyte-like cell phenotype. <h3>Methods</h3> Rabbits <i>New</i><i>Zealand</i> were used as source of adipose-tissues for the isolation of mesenchymal stem cells (MSCs). Preliminary characterization of mesenchymal lineage and differentiation into chondrocyte-like phenotype was confirmed by immunofluorescence analysis using antibodies to collagens I, II (polyclonals), III and CD34 (monoclonals). After 2 and 3 weeks in culture, in the presence or absence of COLV, cell aggregates were fixed for 2 hours in 4% formaldehyde, then dehydrated with etanol and washed with xylene. After embedded in paraffin, different sections were stained with Toluidine blue, Alcian blue and Picrosirius for evaluation in the optic microscope. <h3>Results</h3> Proteoglicans and collagen were demonstrated by Picrosirius staining confirming the existence of collagen expression. Remarkably, compared to control cultures, in the presence of COLV stimulation, MSCs were capable to increase collagen I and II expressions confirming its chondrocyte-like cell phenotype. <h3>Conclusions</h3> COLV may facilitatethe differentiation of rabbitadipose tissue-derived stem cells into a chondrocyte-like phenotype. Further studies are urged in order to evaluate the influence of this protein in the ability of chondrocytes to remodel osteoarthritic joint surface at ultra structural and molecular levels. As a result,the role of COLV in osteoarthritis physiopathology, its clinical significance and therapeutic implications could be elucidated. <h3>Disclosure of Interest</h3> C. Goldenstein-Schainberg: None Declared, I. Cruz: None Declared, R. Fuller: None Declared, A. Velosa: None Declared, S. Carrasco: None Declared, V. Capelozzi: None Declared, N. Yoshinari: None Declared, W. Teodoro Grant/Research support from: FAPESP – 2010/17824-8, Federic Foundation Grants, FFMUSP.
Impact of Maintenance Pemetrexed in the Management of Non-Progressing Malignant Mesotheliomas After Standard Fist-Line Chemotherapy: a Single Institution Experience
Authors: T. Franchina, A. Russo, A. Picone, G.R.R. Ricciardi, F. Raiti, A. Scimone, G. Chiofalo, G. Toscano, V. Adamo
Journal: Annals of Oncology (2015)
AB0398 Responsiveness of a generic and disease specific health related quality of life questionnaire in patients with systemic lupus erythematosus.
Authors: H. Devilliers, Z. Amoura, S. Audia, M. Jolly, P. Bielefeld, L. Arnaud, C. Binquet, J.-F. Besancenot
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Little is published on comparative responsiveness of generic and disease specific Patients reported outcomes (PRO) tool in systemic lupus erythematosus (SLE). <h3>Objectives</h3> To determine and compare the responsiveness and minimally clinical important difference (MCID) of a generic and disease specific PRO measure in SLE. <h3>Methods</h3> SLE patients from a French multicenter study were clinically assessed for activity (SELENA-SLEDAI) at baseline, MOS Short Form 36 (SF-36), LupusQoL, and an overall health status item at baseline (D0), 3 (M3) and 6 (M6) months. Self-reported overall health status item enquired about the impact of lupus on overall health since past visit. Its 7 response options were: -3 "much improved", -2 "moderately improved", -1 "minimally improved", 0 "the same", +1 "minimally worse", +2 "moderately worse" and +3 "much worse". Responsiveness and MCID for SF-36 and LupusQoL domains were determined against +1 or -1 change in overall health status (Anchor-based approach). Descriptives and standardized response mean (SRM) of variations in SF36 and LupusQoL domains were estimated and compared using mixed models methods. <h3>Results</h3> We included 185 SLE patients. Mean (SD) age and SELENA-SLEDAI were 39.6 (10.6) years and 2.6 (3.5). We analyzed 3 time-point data (515 visits) and two consecutive time-point data (306 visits). LupusQoL "Body Image", "Fatigue", and "Burden to others" domains did not change significantly with "worsening" in overall health status; while LupusQoL "body image", and SF-36 "General Health" and "Physical Functioning" domains did not change significantly with an "improvement" in overall health status. SRM in comparable domains of SF-36 and LupusQoL were similar, except for improvement in LupusQoL Physical Health. SRM ranged from small-moderate for all domains on both measures (table). <h3>Conclusions</h3> Both SF-36 and LupusQoL show responsiveness in most domains with change in overall health status. LupusQoL is more responsive to improvement, while SF-36 is more responsive to worsening in overall health status. <h3>Disclosure of Interest</h3> H. Devilliers Consultant for: GlaxoSmithKline, Z. Amoura Consultant for: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Neovacs, Roche, Teva Pharmaceuticals, and UCB Pharma, S. Audia: None Declared, M. Jolly Consultant for: GSK, Medimmune, P. Bielefeld: None Declared, L. Arnaud Consultant for: Amgen, C. Binquet: None Declared, J.-F. Besancenot: None Declared
Case 27-2001
Authors: Noopur Raje, Judith A. Ferry
Journal: New England Journal of Medicine (2001)

Presentation of CaseA 50-year-old man was admitted to the hospital because of marked splenomegaly and anemia.The patient had been in good health until three months earlier, when he began to have progressive exertional dyspnea, aching in the legs, and pain in the left arm (without chest discomfort) after walking 8 to 10 m. The left side of the abdomen became “full,” with increasing abdominal girth, and he had an attack of severe pain in the left flank. More recently, he had sensations of impending syncope, palpitations and dyspnea on minimal exertion, night sweats, diffuse headaches, difficulty concentrating, fatigue, . . .